Barhemsys Disease Interactions

Amisulpride causes dose and concentration-dependent prolongation of the QT interval and should be avoided in patients with congenital long QT syndrome and in patients taking some drugs that prolong the QT interval such as droperidol. ECG monitoring is recommended in patients with pre-existing arrhythmias and cardiac conduction disorders; electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia); congestive heart failure; and in patients taking other medicinal products or with other medical conditions known to prolong the QT interval.

The pharmacokinetics of amisulpride in patients with severe renal impairment have not been adequately studied, however, the drug is known to be substantially excreted by the kidneys and patients with severe renal impairment may have an increased risk of adverse reactions. Avoid the use in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m2). No dosage adjustment is necessary in patients with mild to moderate renal impairment (eGFR 30 mL/min/1.73 m2 and above).